| Document |
Document Title |
|
WO/2023/006019A1 |
Disclosed in the present invention are a polysubstituted benzene PD-L1 inhibitor, a composition and the use thereof. The compound has a structure as represented by general formula (I). The inventor of the present invention confirmed by m...
|
|
WO/2023/003234A1 |
The present invention provides: a novel compound capable of improving the luminous efficiency, stability and lifespan of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2023/001298A1 |
The present invention relates to a method for preparing a hepatitis B virus nucleocapsid inhibitor. Specifically, the method of the present invention obtains a novel method for preparing a compound represented by formula (I) (each group ...
|
|
WO/2023/001818A1 |
The invention relates to a compound having one of the following ionic chemical structures (I), "R" represents an "alkyl" or "O-alkyl" group optionally comprising one or more unsaturations, as a linear or branched chain, of 1 to 30 carbon...
|
|
WO/2023/002443A1 |
The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certai...
|
|
WO/2023/001299A1 |
The present invention relates to a crystal form of a compounds represented by formula (I), and preparation therefor and an application thereof. Specifically, also disclosed in the present invention are a variety of crystal forms of the c...
|
|
WO/2023/002165A1 |
P324681WO 319 ABSTRACT INHIBITOR COMPOUNDS The present invention relates to compounds of Formula (I) that target the MLH1 or MLH1 and PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R6, Y1,...
|
|
WO/2023/003973A1 |
Disclosed herein are inhibitors of deubiquitinating (DUB) enzyme USP7 (Ubiquitin Specific Protease 7). Also provided are methods of treating a disease or disorder modulated by USP7.
|
|
WO/2023/001237A1 |
Disclosed are compounds of formula I or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods related to agonists of glucagon-like peptide-1 receptor (GLP-1R). In particular, the compounds and compos...
|
|
WO/2023/001028A1 |
A heteroaryl-3-piperidinedione compound and the use thereof. Particularly disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/001794A1 |
There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoi...
|
|
WO/2023/288253A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: (I) wherein R1, R2, R3, L, X, and Ar are defined in the present disclosure. The compounds are inhibitors of cyc...
|
|
WO/2023/285497A1 |
The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X, D, R1 to R4, and R6 to R10 are as described herein. Further provided are pharmaceutical composi...
|
|
WO/2023/284782A1 |
A method for screening a compound used for treating or preventing mHTT-related neurodegenerative diseases, target protein used for screening, and a corresponding compound.
|
|
WO/2023/287704A1 |
Provided herein are compounds that bind to BF3 of an androgen receptor (AR), which can modulate the AR for the treatment of Kennedy's disease and for the treatment of cancer.
|
|
WO/2023/286855A1 |
The purpose of the present invention is to provide an excellent agricultural or horticultural plant disease control agent. Provided are: a formamide derivative represented by general formula [I] and the like (in the formula, X1, X2, X3...
|
|
WO/2021/245083A9 |
The present disclosure relates to heterocyclyl pyridine compounds, processes and intermediates for their preparation as well as the uses thereof for controlling phytopathogenic microorganisms, such as phytopathogenic fungi.
|
|
WO/2023/284869A1 |
Provided are a sulfur/phosphorus-containing aryl compound and an application thereof, and specifically disclosed are a compound represented by formula (V) and a pharmaceutically acceptable salt thereof.
|
|
WO/2023/284022A1 |
Provided are a phenanthroimidazole derivative, and a preparation method therefor and an application thereof. The phenanthroimidazole derivative has a structural formula as shown in formula (I), R being an electron donor group, wherein by...
|
|
WO/2023/283256A1 |
Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
|
|
WO/2023/283453A1 |
The disclosure herein provides phenyl acetamide based compounds of Formula (I), (I-a), (II), and pharmaceutical compositions thereof, for the modulation of IL-17A, useful in the treatment of inflammatory conditions such as psoriasis.
|
|
WO/2023/282676A1 |
The present specification relates to a compound and an organic light-emitting element comprising same.
|
|
WO/2023/283428A1 |
Disclosed are compounds l-A and I -B and salts thereof that bind to and modulate cereblon activity. In some embodiments, the binding and modulation of cereblon results in the degradation of IKAROS family zinc finger proteins (e.g., IKZF2).
|
|
WO/2023/283523A1 |
The present disclosure generally relates to 2,3-dihydrobenzo[b][1,4]dioxin-6-yl containing compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclos...
|
|
WO/2023/280182A1 |
Provided in the present invention is a compound serving as a KAT6 inhibitor. Specifically, provided in the present invention is a compound having a structure as represented by the following formula (I) and formula (XIV), or an optical is...
|
|
WO/2023/281271A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
|
WO/2023/279986A1 |
A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.
|
|
WO/2023/279280A1 |
Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical compositi...
|
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
|
WO/2023/274396A1 |
A class of benzazepine heterocyclic compounds that can be used as RORγt agonists and an application thereof in medicine, as well as a pharmaceutical composition comprising this class of compound and an application thereof in medicine. S...
|
|
WO/2023/278600A1 |
The disclosure relates to compounds that act as inhibitors of KRAS; pharmaceutical compositions comprising the compounds; and methods of treating or preventing disorders, including cancer and other proliferation diseases.
|
|
WO/2023/275744A1 |
The present disclosure relates to 3-substituted-5-(1-(quinolin-2-yl)piperidin-4-yl)-1,2,4-oxad
iazole derivatives for use in the treatment and/or prevention of tuberculosis. Formula (I)
|
|
WO/2023/275337A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/274251A1 |
The present invention relates to a polycyclic compound for inhibiting RNA helicase DHX33, and an application of the compound. In particular, the present invention relates to a compound as represented by formula I or a pharmaceutically ac...
|
|
WO/2023/274040A1 |
Provided are a crystal form of a triazolopyridine-substituted indazole compound and a preparation method therefor; and specifically disclosed are a crystal form of a compound as represented by formula (I) and a preparation method therefor.
|
|
WO/2023/277014A1 |
The present invention provides: a compound that has an excellent controlling effect against harmful arthropods, and that is represented by formula (I) [where Z1 and Z2 each represent an oxygen atom or the like, G1 represents CR1a or the ...
|
|
WO/2023/274257A1 |
An imidazole compound as shown in formula I or a pharmaceutically acceptable salt and an intermediate thereof. The imidazole compound as shown in formula I can significantly inhibit AA-induced platelet aggregation, improves MCAO/R-induce...
|
|
WO/2023/275333A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/275796A1 |
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combina...
|
|
WO/2023/274390A1 |
Disclosed are a Bruton's tyrosine kinase and a mutant degrader thereof, or a stereoisomer thereof, or a stereoisomer mixture thereof or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug f...
|
|
WO/2023/275336A1 |
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...
|
|
WO/2023/272720A1 |
PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor comp...
|
|
WO/2023/279105A1 |
Provided herein are azetidine pyrimidine compounds. In particular, provided herein are compounds that affect the function of kinases in a cell, and that are useful as therapeutic agents or with therapeutic agents. The compounds provided ...
|
|
WO/2023/277015A1 |
The present invention provides a compound having outstanding effectiveness against resistant harmful arthropods, a composition containing the same, and a control method. A compound represented by formula (I) [in which R1 denotes a C1-C6 ...
|
|
WO/2022/271901A1 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, N-oxides, and salts thereof, wherein R1, A, R2, R4, R5, L and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds...
|
|
WO/2022/269251A1 |
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: (I) wherein RA, RB, RC and RD are as defined herein.
|
|
WO/2022/268230A1 |
The present invention provides a compound as a KIF18A inhibitor. Specifically, the present invention provides a compound having a structure as represented by the following formula (I), or an optical isomer, pharmaceutically acceptable sa...
|
|
WO/2022/266711A1 |
This disclosure relates to compounds of formula (I), which are modulators of STING. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of using compounds of formula (I) in the treatment or prev...
|
|
WO/2022/271612A1 |
The present disclosure provides a compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2022/270487A1 |
The present invention addresses the problem of providing a compound having an ETA receptor antagonistic activity and others. The problem can be solved by a compound represented by formula (1) [wherein variables are as defined in the desc...
|
